Conference Coverage
June 10, 2024
Innovative Staging System for De Novo Metastatic Breast Cancer Validated Internationally
2024 Society of Surgical Oncology Annual Meeting
June 10, 2024
Osimertinib Therapy Poised to Become New Standard of Care for Unresectable Stage III EGFR-Mutated NSCLC
2024 ASCO Annual Meeting
June 07, 2024
Study Identifies Subset of Patients With Lung Adenocarcinoma Who Have HER2 Alterations
2024 ASCO Annual Meeting
June 05, 2024
Impact of High Blood Insulin Levels on Triple-Negative Breast Cancer Survival in Black Women
ENDO 2024
May 29, 2024
Innovative Staging System for De Novo Metastatic Breast Cancer Validated Internationally
2024 Society of Surgical Oncology Annual Meeting
May 24, 2024
Breast-Conserving Therapy in BRCA-Mutation Carriers: Study Looks at Long-Term Outcomes
2024 Society of Surgical Oncology Annual Meeting
May 13, 2024
Beyond Lung Cancer: Leveraging Machine Learning Techniques to Understand Other Diseases
Quantitative Imaging Workshop XX
May 09, 2024
For Detection of Measurable Residual Disease in Ovarian Cancer, Are Two Methods Better Than One?
SGO 2024 Annual Meeting on Womens Cancer
May 09, 2024
Selective Targeting of PARP1 in Early-Phase Study Shows Activity in Breast Cancer
AACR Annual Meeting 2024
April 25, 2024
Novel MDM2 Inhibitor Shows Activity in Salivary Gland Cancers
2024 Multidisciplinary Head and Neck Cancers Symposium
April 12, 2024
The Lancet Commission on Prostate Cancer: Strategies to Prepare for Predicted Increases in Disease Burden by 2040
European Association of Urology Congress 2024
April 11, 2024
Blood-Based Machine-Learning Assay May Noninvasively Detect Early Ovarian Cancer
AACR Annual Meeting 2024
April 05, 2024
Pembrolizumab May Improve Breast Cancer Outcomes Regardless of Age or Menopausal Status
2024 EBCC
March 26, 2024
Dostarlimab-Based Combinations in Advanced Endometrial Cancer
SGO 2024 Annual Meeting on Womens Cancer
March 22, 2024
Addition of Atezolizumab to Adjuvant Chemotherapy in Triple-Negative Breast Cancer
2024 EBCC
March 22, 2024
Effect of Exercise on Symptom Burden and Quality of Life in Patients With Metastatic Breast Cancer
2024 EBCC
March 22, 2024
Lenvatinib Plus Pembrolizumab Fails to Improve Overall Survival in Recurrent or Metastatic Head and Neck Cancer
2024 Multidisciplinary Head and Neck Cancers Symposium
March 08, 2024
Novel MDM2 Inhibitor for Salivary Gland Cancers
2024 Multidisciplinary Head and Neck Cancers Symposium
February 28, 2024
NATALEE Trial: Long-Term Results on Ribociclib Combination Therapy in Early-Stage Breast Cancer
2023 SABCS
February 28, 2024
Neoadjuvant Chemoimmunotherapy Improves Pathologic Complete Response Rates in Subgroup Analysis of KEYNOTE-756
2023 SABCS
February 16, 2024
Study Examines Real-World Outcomes With Ivosidenib vs Venetoclax in Acute Myeloid Leukemia
2023 ASH
February 16, 2024
AUGMENT-101 Trial: Menin Inhibitor Revumenib Shows Activity in KMT2A-Rearranged Acute Leukemia
2023 ASH
February 15, 2024
Do Patients With Molecular MRD Detected After Colorectal Cancer Surgery Benefit From Adjuvant Chemotherapy?
2024 ASCO GI Cancers Symposium
January 30, 2024
Immune Checkpoint Inhibitor–Based Therapy May Have Comparative Efficacy in Black and White Patients With Metastatic Renal Cell Carcinoma
2024 ASCO GU Cancers Symposium
January 25, 2024
ALL in Adults: Trial Updates and Clinical Considerations for Selecting Consolidation Therapy
2023 NCCN Annual Congress: Hematologic Malignancies
January 22, 2024
NETTER-2: Lu-177 Dotatate for Advanced Gastroenteropancreatic Neuroendocrine Tumors
2024 ASCO GI Cancers Symposium
January 16, 2024
ALINA Trial: Anticancer Activity of Alectinib Reported in Earlier-Stage, ALK-Positive NSCLC
ESMO Congress 2023
December 22, 2023
The Power of Patient Advocacy: 10-Year Study Reveals Increased Survival Rates With Enhanced Advance Care Planning
2023 ASCO Quality Care Symposium
December 21, 2023
Cardiovascular Health of Women Treated for Cancer: Understanding the Long-Term Risks
2023 Global Cardio-Oncology Summit
December 11, 2023
Antibody-Drug Conjugate Makes Progress as Second-Line Therapy for Advanced NSCLC
ESMO Congress 2023
December 08, 2023
Genetic Characteristics of HER2-Low Advanced Breast Cancers May Guide Treatment Selection
2023 SABCS
November 30, 2023
First-Line Selpercatinib: New Standard of Care for RET-Positive Medullary Thyroid Cancer?
ESMO Congress 2023
November 27, 2023
KRAS G12C Inhibitors: Durability of Response, Efficacy in Combination, in NSCLC
IASLC 2023 WCLC
November 27, 2023
Iruplinalkib Demonstrates Improved Efficacy and Tolerance vs Crizotinib in ALK Inhibitor–Naive, Advanced ALK-Positive NSCLC
IASLC 2023 WCLC
November 22, 2023
Cardiac Imaging and Biomarkers for Patients Receiving Cancer Treatment: What Oncologists Need to Know
2023 Global Cardio-Oncology Summit
November 22, 2023
Short-Course Radiotherapy May Reduce Resource Burden of Head and Neck Cancer Treatment in Low- and Middle-Income Countries
2023 ASTRO Annual Meeting
November 22, 2023
Optimizing Treatment Selection for Newly Diagnosed and Secondary AML: Focus on Cytogenetic and Molecular Data
2023 NCCN Annual Congress: Hematologic Malignancies
November 17, 2023
Extensive-Stage Small Cell Lung Cancer: Triplet Combination vs Chemotherapy Alone
IASLC 2023 WCLC
November 01, 2023
Insurance Coverage Disruptions May Reduce Rate of Cancer Screenings
2023 ASCO Quality Care Symposium
October 26, 2023
Text Message–Based Prescreening Could Benefit Patients Receiving Immunotherapy
2023 ASCO Quality Care Symposium
October 25, 2023
NATALEE Trial: Quality of Life Maintained for Many Patients Treated With Ribociclib for Early-Stage Breast Cancer
2023 ESMO Virtual Plenary
October 17, 2023
Can Younger Women With Hormone Receptor–Positive Breast Cancer Safely Pause Endocrine Therapy to Pursue Pregnancy?
2022 San Antonio Breast Cancer Symposium
October 17, 2023
EMERALD Trial: Elacestrant vs Standard Endocrine Monotherapy for Advanced Breast Cancer After CDK4/6 Inhibition
2022 San Antonio Breast Cancer Symposium
October 17, 2023
Should CDK4/6 Inhibitors Be a First-Line Option for Advanced Hormone Receptor–Positive, HER2-Negative Breast Cancer?
2023 ASCO Annual Meeting
October 17, 2023
Expert Point of View: Meritxell Bellet Ezquerra, MD, PhD, and Sung-Bae Kim, MD, PhD
ESMO Congress 2022
October 03, 2023
Precision Medicine Navigators May Increase Genomic Testing Rates Among Black Patients With Prostate Cancer
2023 ASTRO Annual Meeting
September 26, 2023
Understanding the Treatment of Waldenström’s Macroglobulinemia
2023 Debates and Didactics in Hematology and Oncology Conference
September 20, 2023
CLL14: Long-Term Results of Fixed-Duration Venetoclax Plus Obinutuzumab in Elderly Patients With CLL
EHA Hybrid Congress 2023
September 20, 2023
Potential of Quizartinib for Improving Outcomes in Acute Myeloid Leukemia
EHA Hybrid Congress 2023
September 14, 2023
Cabozantinib Plus Atezolizumab Warrants Further Study in Treatment of Advanced Head and Neck Cancer
SITC 2022
September 14, 2023
Could Fluorouracil-Free First-Line Regimen Challenge the Standard of Care in Advanced Head and Neck Cancer?
ESMO Congress 2022
September 14, 2023
First-in-Class Agent Given With Chemoradiotherapy Improves Survival in Locally Advanced Head and Neck Cancer, Study Finds
ESMO Congress 2022
September 11, 2023
Study Shows Exercise May Improve Sexual Function in Men With Prostate Cancer
2023 ASCO Breakthrough Meeting
September 11, 2023
Expert Point of View: Peter Paul Yu, MD, FACP, FASCO
2023 ASCO Breakthrough Meeting
August 24, 2023
Liquid Biopsy Assay Demonstrated Effectiveness in Early Cancer Detection in Asymptomatic Individuals in Vietnam
2023 ASCO Breakthrough Meeting
August 18, 2023
Darolutamide Plus Androgen-Deprivation Therapy and Docetaxel in Metastatic Hormone-Sensitive Prostate Cancer
2023 ASCO Genitourinary Cancers Symposium
August 18, 2023
CheckMate 274: Continued Disease-Free Survival Benefits With Adjuvant Nivolumab in High-Risk Urothelial Carcinoma
2023 ASCO Genitourinary Cancers Symposium
August 18, 2023
CLEAR Trial: Continued Survival Benefit With First-Line Lenvatinib Plus Pembrolizumab in Advanced Kidney Cancer
2023 ASCO Annual Meeting
August 18, 2023
PROpel Trial: Improvement in Progression-Free Survival With First-Line Olaparib Plus Abiraterone in Metastatic Prostate Cancer
2023 ASCO Genitourinary Cancers Symposium
August 17, 2023
ZUMA-7: Primary Overall Survival Analysis Supports Axicabtagene Ciloleucel as Second-Line Therapy in Advanced Lymphoma
2023 ASCO Annual Meeting
July 10, 2023
Study Finds Preoperative MRI Does Not Significantly Impact Margin Status in Patients With Breast Cancer
24th ASBrS Annual Meeting
June 15, 2023
Surveillance Mammography Rates After Breast Cancer Treatment Remain High, Irrespective of Life Expectancy
24th ASBrS Annual Meeting
June 15, 2023
Novel Hormone Receptor–Driven Therapies Tackling Endocrine Resistance in Breast Cancer
2023 Miami Breast Cancer Conference
June 09, 2023
HER3-Targeting Antibody-Drug Conjugates Show Encouraging Results in Breast Cancer Subtypes
ESMO Breast Cancer Annual Congress 2023
June 07, 2023
CodeBreaK 200: Sotorasib Offers Improved Quality of Life for Patients With Previously Treated NSCLC
European Lung Cancer Congress 2023
May 25, 2023
Immunotherapy/Chemotherapy Combination Prolongs Survival in Advanced Biliary Tract Cancers
AACR Annual Meeting 2023
May 19, 2023
NCCN Clinical Practice Guidelines in Oncology: 2023 Updates
NCCN 2023 Annual Conference
May 12, 2023
CLL2-GIVe Trial: Regimen of Obinutuzumab, Ibrutinib, and Venetoclax Effective in High-Risk CLL
2022 ASH Annual Meeting and Exposition
May 11, 2023
Poor Tolerability Appears to Hinder Benefit of Adavosertib in Uterine Serous Carcinoma
SGO 2023 Annual Meeting on Women’s Cancer
May 05, 2023
Study Explores Genomic Basis of Racial Disparities Among Patients With Colorectal Cancer
AACR Annual Meeting 2023
May 04, 2023
Emerging Success With Novel Targeted Therapies in Endocrine-Resistant Metastatic Breast Cancer
2023 Miami Breast Cancer Conference
May 01, 2023
Does Surveillance Mammography Benefit Geriatric Patients With Breast Cancer?
24th ASBrS Annual Meeting
April 25, 2023
How Effectively Are You Helping Patients With Cancer at the End of Life?
2023 Miami Breast Cancer Conference
April 18, 2023
Liquid Biopsy–Based Multicancer Early Detection Test May Find Early-Stage and Low DNA–Shedding Cancers
AACR Annual Meeting 2023
April 12, 2023
ELCC 2023: New Data on Amivantamab-vmjw in Patients With Advanced NSCLC and EGFR Exon 20 Insertion Mutations
European Lung Cancer Congress 2023
March 30, 2023
Time-Related and Financial Burdens May Impact Quality of Life for Patients With Gynecologic Cancer
SGO 2023 Annual Meeting on Women’s Cancer
March 29, 2023
Positive Outcomes Demonstrated in Patients With Ovarian Cancer Treated With Olaparib Prior to Surgical Intervention and Subsequent Chemotherapy
SGO 2023 Annual Meeting on Women’s Cancer
March 13, 2023
Digital Rectal Examination Fails to Detect Early Prostate Cancer, Study Shows
2023 EAU Annual Congress
February 24, 2023
Expert Point of View: Adam M. Brufsky, MD
2022 San Antonio Breast Cancer Symposium
February 24, 2023
What Can Be Learned From Negative Findings of Two Trials in Biliary Tract Cancer
2023 ASCO Gastrointestinal Cancers Symposium
February 16, 2023
Ruxolitinib Demonstrates Clinical Activity in a Phase II Trial of Chronic Myelomonocytic Leukemia
2022 ASH Annual Meeting and Exposition
February 13, 2023
Subset of Patients With Advanced Gastric Cancer May Benefit From Claudin18.2-Targeted Agent Zolbetuximab
2023 ASCO Gastrointestinal Cancers Symposium
January 31, 2023
Subset of Patients With Advanced Gastric/GEJ Cancer May Benefit From CLDN18.2-Targeted Drug Zolbetuximab: SPOTLIGHT Study
2023 ASCO Gastrointestinal Cancers Symposium
January 31, 2023
How Experts Treat Mantle Cell Lymphoma in First Complete Response
2022 Pan Pacific Lymphoma Conference
January 25, 2023
Cabozantinib Plus Atezolizumab Warrants Further Study in Treatment of Advanced Head and Neck Cancer
SITC 2022
January 18, 2023
Expert Point of View: Jeremy S. Abramson, MD
2022 ASH Annual Meeting and Exposition
January 25, 2022
Expert Point of View: Anne Blaes, MD, MS, and Virginia Kaklamani, MD
2021 San Antonio Breast Cancer Symposium
January 04, 2022
Identifying Women With Triple-Negative Breast Cancer Who May Benefit From Pembrolizumab Plus Chemotherapy
2021 San Antonio Breast Cancer Symposium
December 21, 2021
Expert Point of View: Matthew J. Ellis, MB, BChir, PhD, FACP
2021 San Antonio Breast Cancer Symposium
October 13, 2021
Novel HER2-Targeted Therapies Pose Sequencing Challenges
38th Annual Miami Breast Cancer Conference
October 10, 2021
Benefits Seen With Lurbinectedin Plus Doxorubicin in Small Cell Lung Cancer—but Primary Endpoint Missed
IASLC 2021 World Conference on Lung Cancer
September 17, 2021
Niraparib Plus Bevacizumab Shows Clinical Benefit in Advanced Ovarian Cancer
SGO 2021 Virtual Annual Meeting on Womens Cancer
September 16, 2021
CheckMate 648: First-Line Nivolumab Regimens Improve Survival in Esophageal Squamous Cell Carcinoma
2021 ASCO Annual Meeting
September 10, 2021
Safety, Efficacy of Neoadjuvant Pertuzumab Plus Trastuzumab Maintained in Final Analysis of BERENICE Trial
ESMO Breast Cancer Virtual Congress 2021
September 01, 2021
Neoadjuvant Durvalumab Improves Long-Term Outcomes in the GeparNuevo Trial
2021 ASCO Annual Meeting
August 16, 2021
Phase III GLOW Trial: Improved Outcomes With First-Line Ibrutinib Plus Venetoclax in Elderly Patients With CLL
EHA 2021 Virtual Congress
August 16, 2021
Zanubrutinib Superior to Ibrutinib for CLL/SLL in Phase III ALPINE Trial
EHA 2021 Virtual Congress
August 02, 2021
Breast Cancer in 2030: Predictions From a Breast Cancer Luminary
38th Annual Miami Breast Cancer Conference
June 11, 2021
Adjuvant Imatinib Therapy Offers Survival Benefit in Patients With Resected GIST, but Team Effort May Be Needed to Reduce Early Discontinuation Rates
SSO 2021 International Conference on Surgical Cancer Care
June 10, 2021
New Approaches Needed for Patients With Locoregional Breast Cancer Progression During Neoadjuvant Systemic Therapy
22nd ASBrS Annual Meeting
May 25, 2021
Dual BRAF/MEK Inhibition Under Study in BRAF V600E–Mutant Gliomas
AACR Annual Meeting 2021
May 25, 2021
Selpercatinib Makes Inroads in Other RET Fusion–Positive Tumor Types
AACR Annual Meeting 2021
May 25, 2021
Frailty Can Be a Serious Issue in Ovarian Cancer
SGO 2021 Virtual Annual Meeting on Womens Cancer
April 21, 2021
Nivolumab: First Adjuvant Immunotherapy to Show Survival Benefit in High-Risk Muscle-Invasive Urothelial Cancer
2021 Genitourinary Cancers Symposium
March 25, 2021
Repurposing Available Drugs for COVID-19: An Ongoing Initiative
AACR Virtual Meeting: COVID-19 and Cancer 2021
March 10, 2021
In Cholangiocarcinoma, Does Chemotherapy Response Vary According to FGFR2 Status?
2021 Gastrointestinal Cancers Symposium
March 01, 2021
Is Trop-2 Expression Associated With Benefit From Sacituzumab Govitecan-hziy?
2020 San Antonio Breast Cancer Symposium
February 25, 2021
SIMPLIFY Trials: JAK Inhibitor Yields Long-Term Survival Benefit and Transfusion Independence in Myelofibrosis
2020 ASH Annual Meeting & Exposition
February 10, 2021
Severity of Patients’ Symptoms May Be Underrecognized During and After Breast Radiotherapy
2020 San Antonio Breast Cancer Symposium
January 25, 2021
A Tale of Two CDK4/6 Inhibitors in Early Breast Cancer
2020 San Antonio Breast Cancer Symposium
January 25, 2021
Oral Azacitidine Is Noninferior to Placebo for Health-Related Quality of Life in AML
2020 ASH Annual Meeting & Exposition